Reactive oxygen species and melanoma: an explanation for gender differences in survival?
Arjen Joosse(Erasmus MC), J.W.W. Coebergh(Erasmus University Rotterdam), Tamar Nijsten(Erasmus MC), Casper H.J. van Eijck(Erasmus MC), Esther de Vries(Tilburg University), Alexander M.M. Eggermont(University Medical Center Utrecht)
Cited by 62
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
|CA A Cancer Journal for Clinicians|2017|2.3k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k